| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T67894 | ||||
| Target Name | Toll-like receptor 3 | ||||
| Target Type | Clinical Trial |
||||
| Action against Disease Model | BCG65-E7 | Target of vaccines. Utilizing the E7-expressing murine t uMor cell line, TC-1, as a model of cervical carcinoma, an immunotherapy based on the administration of an adjuvant-freefusion protein comprised of Mycobacteri uM bovis BCG Hsp65 linked to HPV16 E7 (HspE7) has been developed. Initial in vitro analyses indicate that immunization with HspE7 results in the induction of atype 1 immune response based on the pattern of secreted cytokines and the presence of cytolytic activity following antigenic recall. | [552225] | Drug Info | |
| The Effect of Target Knockout, Knockdown or Genetic Variations | Although dsRNA is typically recognized by Toll-like receptor 3, Toll-like receptor 3 knockout mice developed arthritis, indicating that some other receptors are instr uMental inthe inducing of in?ammation. Our results from in vitro experiments indicate that proin?ammatory cytokines and chemokines stimulating monocyte in?ux were readily triggered in response to stimulation with dsRNA. These ?ndings demonstrate that viral dsRNA is clearly arthritogenic. Importantly, macrophages and their products play an important role in the development of arthritis triggered by dsRNA. | [552225] | |||
| References | |||||
| Ref 552225 | Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol. 2000 Aug;121(2):216-25. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.